300 related articles for article (PubMed ID: 15845937)
1. A case of stunning of lung and bone metastases of papillary thyroid cancer after a therapeutic dose (3.7 GBq) of 131I and review of the literature: implications for sequential treatments.
Leger AF; Pellan M; Dagousset F; Chevalier A; Keller I; Clerc J
Br J Radiol; 2005 May; 78(929):428-32. PubMed ID: 15845937
[TBL] [Abstract][Full Text] [Related]
2. 131I therapeutic efficacy is not influenced by stunning after diagnostic whole-body scanning.
Dam HQ; Kim SM; Lin HC; Intenzo CM
Radiology; 2004 Aug; 232(2):527-33. PubMed ID: 15286323
[TBL] [Abstract][Full Text] [Related]
3. The effects of radioactive iodine in thyroid remnant ablation and treatment of well differentiated thyroid carcinoma.
Lin JD; Kao PF; Chao TC
Br J Radiol; 1998 Mar; 71(843):307-13. PubMed ID: 9616241
[TBL] [Abstract][Full Text] [Related]
4. Self-stunning in thyroid ablation: evidence from comparative studies of diagnostic 131I and 123I.
Hilditch TE; Dempsey MF; Bolster AA; McMenemin RM; Reed NS
Eur J Nucl Med Mol Imaging; 2002 Jun; 29(6):783-8. PubMed ID: 12029552
[TBL] [Abstract][Full Text] [Related]
5. Decreased uptake after fractionated ablative doses of iodine-131.
Wu HS; Hseu HH; Lin WY; Wang SJ; Liu YC
Eur J Nucl Med Mol Imaging; 2005 Feb; 32(2):167-73. PubMed ID: 15351912
[TBL] [Abstract][Full Text] [Related]
6. [Results of radioiodine therapy in 47 patients with distant metastases of differentiated thyroid carcinoma].
Miyamoto S; Kasagi K; Endo K; Iida Y; Hidaka A; Hatabu H; Konishi J
Nihon Igaku Hoshasen Gakkai Zasshi; 1991 Jul; 51(7):810-21. PubMed ID: 1891347
[TBL] [Abstract][Full Text] [Related]
7. Comparison of outcomes after (123)I versus (131)I pre-ablation imaging before radioiodine ablation in differentiated thyroid carcinoma.
Silberstein EB
J Nucl Med; 2007 Jul; 48(7):1043-6. PubMed ID: 17574976
[TBL] [Abstract][Full Text] [Related]
8. Decreased uptake of therapeutic doses of iodine-131 after 185-MBq iodine-131 diagnostic imaging for thyroid remnants in differentiated thyroid carcinoma.
Leger FA; Izembart M; Dagousset F; Barritault L; Baillet G; Chevalier A; Clerc J
Eur J Nucl Med; 1998 Mar; 25(3):242-6. PubMed ID: 9580856
[TBL] [Abstract][Full Text] [Related]
9. Influence of diagnostic and therapeutic doses on thyroid remnant ablation rates.
Karam M; Gianoukakis A; Feustel PJ; Cheema A; Postal ES; Cooper JA
Nucl Med Commun; 2003 May; 24(5):489-95. PubMed ID: 12717064
[TBL] [Abstract][Full Text] [Related]
10. Stunning effects after a diagnostic dose of iodine-131.
Kao CH; Yen TC
Nuklearmedizin; 1998 Jan; 37(1):30-2. PubMed ID: 9467167
[TBL] [Abstract][Full Text] [Related]
11. [Results of radioiodine therapy in patients with pulmonary metastases of differentiated thyroid cancer].
Ono Y; Yamamoto Y; Nishiyama Y; Nakano S; Takahashi K; Kawasaki Y; Satoh K; Ohkawa M; Tanabe M
Kaku Igaku; 2000 Nov; 37(6):661-70. PubMed ID: 11193452
[TBL] [Abstract][Full Text] [Related]
12. Stunning with 131I diagnostic whole-body imaging of patients with thyroid cancer.
Gerard SK; Dam HQ
Radiology; 2005 Mar; 234(3):972-3; author reply 973-4. PubMed ID: 15734947
[No Abstract] [Full Text] [Related]
13. [Non-iodine-absorbing metastasis of differentiated thyroid cancer--therapeutic probe with 13-cis retinoic acid].
Kaniewski M; Czetwertyńska M; Godlewska P; Drac-Kaniewska J
Wiad Lek; 2001; 54 Suppl 1():297-300. PubMed ID: 12182038
[TBL] [Abstract][Full Text] [Related]
14. Thyroid stunning in clinical practice: is it a real problem?
Filesi M; Colandrea M; Montesano T; D'Apollo R; Ronga G
Minerva Endocrinol; 2009 Mar; 34(1):29-36. PubMed ID: 19209126
[TBL] [Abstract][Full Text] [Related]
15. The clinical effects of thyroid stunning after diagnostic whole-body scanning with 185 MBq 131I.
Lees W; Mansberg R; Roberts J; Towson J; Chua E; Turtle J
Eur J Nucl Med Mol Imaging; 2002 Nov; 29(11):1421-7. PubMed ID: 12397458
[TBL] [Abstract][Full Text] [Related]
16. "High-dose" radioiodine therapy in advanced differentiated thyroid carcinoma.
Menzel C; Grünwald F; Schomburg A; Palmedo H; Bender H; Späth G; Biersack HJ
J Nucl Med; 1996 Sep; 37(9):1496-503. PubMed ID: 8790201
[TBL] [Abstract][Full Text] [Related]
17. Radioactive iodine treatment and external radiotherapy for lung and bone metastases from thyroid carcinoma.
Schlumberger M; Challeton C; De Vathaire F; Travagli JP; Gardet P; Lumbroso JD; Francese C; Fontaine F; Ricard M; Parmentier C
J Nucl Med; 1996 Apr; 37(4):598-605. PubMed ID: 8691248
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of dosimetry of radioiodine therapy in benign and malignant thyroid disorders by means of iodine-124 and PET.
Eschmann SM; Reischl G; Bilger K; Kupferschläger J; Thelen MH; Dohmen BM; Besenfelder H; Bares R
Eur J Nucl Med Mol Imaging; 2002 Jun; 29(6):760-7. PubMed ID: 12029549
[TBL] [Abstract][Full Text] [Related]
19. Cumulative doses of adjunct 131I treatment depend on location of residual thyroid tissue after total thyroidectomy in differentiated thyroid cancer.
Saint-Vil D; Emran MA; Lambert R; Alos N; Turpin S; Huot C
J Pediatr Surg; 2007 May; 42(5):853-6. PubMed ID: 17502198
[TBL] [Abstract][Full Text] [Related]
20. Lung dosimetry for radioiodine treatment planning in the case of diffuse lung metastases.
Song H; He B; Prideaux A; Du Y; Frey E; Kasecamp W; Ladenson PW; Wahl RL; Sgouros G
J Nucl Med; 2006 Dec; 47(12):1985-94. PubMed ID: 17138741
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
